clinical trial · NCT06104592
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 27
Large B-cell LymphomaRelapsed Non-Hodgkin LymphomaComprehensive Ablative Bridging Irradiation (CABI)Chimeric Antigen Receptor T-Cell Therapy
brief summary
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
started
Nov 8, 2023
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Mar 31, 2026
official title
Phase 2, Single-Arm Trial of Comprehensive Ablative Bridging Irradiation (CABI) Prior to CD19 CAR-T Cell Therapy in High-Risk, Relapsed or Refractory Large B Cell Lymphoma in Patients With Bulky Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol